[A17-36] Baricitinib (rheumatoid arthritis) - Addendum to commission A17-14
Last updated 21.09.2017
Commission awarded on 08.08.2017 by the Federal Joint Committee (G-BA).
Muscles, bones and joints
Moderate to severe rheumatoid arthritis in adult patients who have responded inadequately to pretreatment
Neither advantage nor disadvantage proven from the consideration of the total study population of the JADV study for research questions 2 and 3 of dossier assessment A17-14
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A17-14||Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V||Commission completed|